Table 4. Concordance between the EGFR mutation status in tissue and plasma samples in advanced or metastatic NSCLC TKI-naïve patients.

	Tissue Sample
	EGFR mutation (n=23)	EGFR wild-type (n=81)
cfDNA
EGFR mutation (n=18)	18	0
EGFR wild-type (n=86)	5	81
Sensitivity (95%, CI), %	78.3 (89.2–97.9)
Specificity (95%, CI), %	100 (95.5–100)
PPV (95%, CI), %	100 (82.4–100)
NPV (95%, CI), %	94.2 (87.1–97.5)
Overall concordance (95%, CI), %	95.2 (89.2–97.9)

n, sample size; cfDNA, circulating-free DNA; EGFR, epdermal growth factor receptor; NPV, negative predictive value; PPV, positive predictive value.